BLOOM BIOMED INTERNATIONAL CO., LTD.
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
Deeply specializing in gynecological medical devices, plastic surgery medical devices (breast augmentation), orthopedic medical devices, neurosurgery, urological medical devices, ENT (otorhinolaryngology), and general surgery.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2015
Unified Business No.
24973313
Status
Active
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
The team of BLOOM BIOMED INTERNATIONAL CO., LTD. is composed of professional managers who have received excellent educational foundations both domestically and abroad and have served in major international pharmaceutical companies. We aspire to become a global healthcare leader. Health is the foundation of enjoying a beautiful life, and this philosophy is precisely the driving force behind our commitment to continuously providing innovative medical devices.
Since accepting the mission from Surgical Specialties Corporation, the world's second-largest barbed suture manufacturer, in 2015, we have promoted Quill barbed sutures and designated sutures for laparoscopic or Da Vinci surgery in more than 50 teaching hospitals domestically. By being adept at utilizing our technological expertise and global resources, every surgical patient can improve their quality of life after surgery.
Since 2017, we have taken on the Class III medical implants from Sebbin in Paris, France. From the Renaissance to today's annual fashion design exhibitions, European aesthetic design has always been what most artists yearn for in their hearts. In addition, among the numerous international journals published over the past ten years, clinical evidence shows that the capsular contracture rate for first-time surgery patients is less than 1%. To date, our business has expanded to more than 60 countries, deeply rooted in the European region, and has become the number one breast implant brand for micro-textured surfaces in South Korea.
The medical aesthetics industry is a conscientious business tasked with maintaining public health and protecting lives. To fully fulfill our responsibility as a global medical aesthetics leader, BLOOM BIOMED INTERNATIONAL CO., LTD. actively cooperates with healthcare providers, medical professionals, government agencies, civil groups, non-profit organizations, and other entities worldwide to provide more comprehensive medical care, ensuring that surgical patients everywhere can enjoy safe, effective, and affordable medical resources.
Upholding the core value of medical innovation, BLOOM BIOMED INTERNATIONAL CO., LTD. continues to invest research resources into medical device research and development, developing medical devices that make major breakthroughs in improving health.
Whether in research and development, manufacturing, or sales, we strive to establish patient safety, improve quality of life, and create life value as our ultimate guidance.
(The content above was translated by AI.)
Since accepting the mission from Surgical Specialties Corporation, the world's second-largest barbed suture manufacturer, in 2015, we have promoted Quill barbed sutures and designated sutures for laparoscopic or Da Vinci surgery in more than 50 teaching hospitals domestically. By being adept at utilizing our technological expertise and global resources, every surgical patient can improve their quality of life after surgery.
Since 2017, we have taken on the Class III medical implants from Sebbin in Paris, France. From the Renaissance to today's annual fashion design exhibitions, European aesthetic design has always been what most artists yearn for in their hearts. In addition, among the numerous international journals published over the past ten years, clinical evidence shows that the capsular contracture rate for first-time surgery patients is less than 1%. To date, our business has expanded to more than 60 countries, deeply rooted in the European region, and has become the number one breast implant brand for micro-textured surfaces in South Korea.
The medical aesthetics industry is a conscientious business tasked with maintaining public health and protecting lives. To fully fulfill our responsibility as a global medical aesthetics leader, BLOOM BIOMED INTERNATIONAL CO., LTD. actively cooperates with healthcare providers, medical professionals, government agencies, civil groups, non-profit organizations, and other entities worldwide to provide more comprehensive medical care, ensuring that surgical patients everywhere can enjoy safe, effective, and affordable medical resources.
Upholding the core value of medical innovation, BLOOM BIOMED INTERNATIONAL CO., LTD. continues to invest research resources into medical device research and development, developing medical devices that make major breakthroughs in improving health.
Whether in research and development, manufacturing, or sales, we strive to establish patient safety, improve quality of life, and create life value as our ultimate guidance.
(The content above was translated by AI.)
